Radioiodine therapy for Graves' disease: Problems and new developments;Die radioiodtherapie des Morbus basedow - Probleme und neue entwicklungen

Zeitschrift fur Arztliche Fortbildung und Qualitatssicherung

Volumn 98, Issue SUPPL. 5, 2004, Pages 55-62

  Reiners, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Cost effectiveness; Dose concepts targets; Graves' disease; Indication; Preparation procedure; Radioiodine treatment; Side effects risks

Indexed keywords

ANTITHYROID AGENT; CORTICOSTEROID; RADIOACTIVE IODINE;

CIGARETTE SMOKING; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DOSIMETRY; GERMANY; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; PROPHYLAXIS; RADIATION DOSE FRACTIONATION; RISK ASSESSMENT; SIDE EFFECT; TREATMENT INDICATION;

EID: 3042692727     PISSN: 14317621     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (95)

1. Ahmad AM, Ahmad M, Young ET (2002) Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis. Eur J Endocrinol 146: 767-775
2. 131I Therapy for the Treatment of Hyperthyroidism Caused by Graves' Disease. J Clin Endocrinol Metab 87: 1073-1077
3. Allahabadia A, Daykin J, Holder R L, Sheppard MC, Gough SCL, Franklyn JA (2000) Age and Gender Predict the Outcome of Treatment for Graves' Hyperthyroidism. J Clin Endocrinol Metab 85: 1038-1042
4. Allahabadia A, Daykin J, Sheppard MC, Gough SCL, Franklyn JA (2001) Radioiodine Treatment of Hyperthyroidism - Prognostic Factors for Outcome. J Clin Endocrinol Metab 86: 3611-3617
5. Alquist J (1999) Radioiodine and thyroid eye disease. BMJ 319: 1133
6. Andrade VA, Gross JL, Maia AL (1999) Effect of Methimazole Pretreatment on Serum Thyroid Hormone Levels after Radioactive Treatment in Graves' Hyperthyroidism. J Clin Endocrinol Metab 84: 4012-4016
7. Andrade V, Gross JL, Maia AL (2001) The Effect of Methimazole Pretreatment on the Efficacy of Radioactive Iodine Therapy in Graves' Hyperthyroidism: One-Year-Follow-Up of a Prospective, Randomized Study. J Clin Endocrinol Metab 86: 3488-3493
8. Bajnok L, Mezosi E, Nagy E, Szabo J, Sztojka I, Varga J, Galuska L, Leovey A (1999) Calculation of the Radioiodine Dose for the Treatment of Graves' Hyperthyroidism: Is More than Seven-Thousand Rad Target Dose Necessary? Thyroid 9: 865-869
9. Bal CS, Kumar A, Pandey RM (2002) A Randomized Controlled Trial to Evaluate the Adjuvant Effect of Lithium on Radioiodine Treatment of Hyperthyroidism. Thyroid 12: 399-405
10. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A (1998) Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy. N Engl J Med 338: 73-78
11. Bartalena L, Marcocci C, Pinchera A (1998) On the Effects of Radioiodine Therapy on Graves' Ophthalmopathy. Thyroid 8: 533-534
12. Berg GEB, Michanek AMK, Holmberg ECV, Fink M (1996) Iodine-131 Treatment of Hyperthyroidism: Significance of Effective Half-live Measurements. J Nucl Med 37: 228-232
13. Bockisch A, Jamitzky T, Derwanz R, Biersack HJ (1993) Optimized Dose Planning of Radioiodine Therapy of Benign Thyroidal Diseases. J Nucl Med 34: 1632-1638
14. Bogazzi F, Bartalena L, Brogioni S, Scarcello G, Burelli A, Campomori A, Manetti L, Rossi G, Pinchera A, Martino E (1999) Comparison of Radioiodine with Radioiodine plus Lithium in the Treatment of Graves' Hyperthyroidism. J Clin Endocrinol Metab 84: 499-503
15. Bogazzi F, Bartalena L, Campomori A, Brogioni S, Traino C, de Martino F, Rossi G, Lippi F, Pinchera A, Martino E (2002) Treatment with Lithium Prevents Serum Thyroid Hormone Increase after Thionamide Withdrawal and Radioiodine Therapy in Patients with Graves' Disease. J Clin Endocrinol Metab 87: 4490-4495
16. Bogazzi F, Martino E, Bartalena L (2003) Antithyroid drug treatment prior to radioiodine therapy for Graves' disease: Yes or no? J Endocrinol Invest 26: 174-176
17. Bonnema SJ, Bartalena L, Toft AD, Hegedüs L (2002) Controversies in radioiodine therapy: relation to ophthalmopathy, the possible radioprotective effect of antithyroid drugs, and use in large goitres. Eur J Endocrinol 147: 1-11
18. 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur J Endocrinol 149: 485-492
19. Brabant G (2004) Therapie der Hyperthyreose. Med Welt 55: 17-20
20. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS (2002) The Effect of Methimazole on Cure Rates After Radioiodine Treatment for Graves' Hyperthyroidism: A Randomized Clinical Trial. Thyroid 12: 135-139
21. 131I treatment of thyrotoxicosis. J Endocrinol Invest 2: 303-304
22. Cheetham TD, Wraight P, Hughes IA, Barnes ND (1998) Radioiodine treatment of Graves' disease in young people. Horm Res 49: 258-262
23. Col NF, Surks MI, Daniels GH (2004) Subclinical Thyroid Disease - Clinical Applications. JAMA 291: 239-243
24. Dale J, Daykin J, Holder R, Sheppard MC, Franklyn JA (2001) Clin Endocrinol 55: 233-239
25. Dietlein M, Dressler J, Grünwald F, Eisner B, Moser E, Reiners C, Schicha H, Schneider P, Schober O (2002) Leitlinie zur Radioiodtherapie (RIT) bei benignen Schilddrüsenerkrankungen. www:awmf-online.de
26. Dietlein M, Moka D, Dederichs B, Hunsche E, Lauterbach KW, Schicha H (1999) Kosten-Effektivitäts-Analyse: Radioiod oder thyreostatische Medikation bei der Primärbehandlung der Immunhyperthyreose. Nuklearmedizin 38: 7-14
27. Dietlein M, Moka D, Schmidt M, Theissen P, Schicha H (2003) Prävention, Screening und Therapie gutartiger Schilddrüsenerkrankungen unter dem Aspekt von Kosten und Nutzen. Nuklearmedizin 42: 181-189
28. Doi SAR, Loutfi I, Al-Shoumer K AS (2001) A mathematical model of optimized radioiodine-131 therapy of Graves' hyperthyroidism. BMC Nuclear Medicine 1: 1-10
29. Eising EG, Görges R, Freudenberg L, Kanja J, Bockisch A (2002) Influence of Therapy with Iodine-131 on Thyroid Tissue Pattern in Colour and Power Doppler Sonography. Clin Radiol 57: 646-651
30. Foley TP, Charron M (1997) Radioiodine treatment of juvenile Graves' disease. Exp Clin Endocrinol Diabetes 105 (Suppl 4): 61-65
31. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P (1998) Mortality after the treatment of hyperthyroidism with radioactive iodine. New Engl J Med 338: 712-718
32. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353: 2111-2115
33. Glinoer D, de Nayer P, Bex M and the Belgian Collaborative Study Group on Graves' Disease (2001) Effects of L-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 144: 475-483
34. Grueters A (1998) Treatment of Graves' disease in children and adolescents. Horm Res 49: 255-257
35. 131Iodine Therapy on the Course of Graves' Ophthalmopathy: A Quantitative Analysis of Extraocular Muscle Volumes Using Orbital Magnetic Resonance Imaging. Thyroid 11: 959-965
36. Haase A, Bähre M, Lauer I, Meller B, Richter E (1999) Radioiodine therapy in Graves' hyperthyroidism: Determination of individual optimum target dose. Exp Clin Endocrinol Diabetes 108: 133-137
37. Hall P, Holm L-E (1997) Late Consequences of Radioiodine for Diagnosis and Therapy in Sweden. Thyroid 7: 205-208
38. Kalinyak JE, McDougall IR (2003) How Should the Dose of Iodine-131 be Determined in the Treatment of Graves' Hyperthyroidism? J Clin Endocrinol Metab 88: 975-977
39. Kok SW, Smit JW, de Craen AJM, Goslings BM, van Eck-Smit BLF, Romijn JA (2000) Clinical outcome after standardizes verses dosimetric radioiodine treatment of hyperthyroidism: an equivalent study. Nucl Med Communic 21: 1071-1078
40. Körber C, Schneider P, Körber-Hafner N, Hänscheid H, Reiners C (2001) Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre? Eur J Nucl Med 28: 1360-1364
41. Kraiem Z, Newfield RS (2001) Graves' Disease in Childhood. J Pediatric Endocinol 14: 229-243
42. 131I and thyroid-associated ophthalmopathy. Eur J Endocrinol 143: 155-160
43. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA (2003) A Randomized Comparison of Radioiodine Doses in Graves' Hyperthyroidism. J Clin Endocrinol Metab 88: 978-983
44. Lind P (2001) Die ablative Therapie der Immunhyperthyreose unter spezieller Berücksichtigung der endokrinen Orbitopathie. Acta Med Austriaca 28: 105-107
45. Lind P (2002) Strategies of radioiodine therapy for Graves' disease. Eur J Nucl Med 29 (Suppl 2): 453-457
46. Ljunggren J-G, Törring O, Wallin G, Taube A, Tallstedt L, Hamberger B, Lundell G (1998) Quality of Life Aspects and Costs in Treatment of Graves' Hyperthyroidism with Antithyroid Drugs, Surgery, or Radioiodine: Results from a Prospective, Randomized Study. Thyroid 8: 653-659
47. Manso PG, Furlanetto RP, Wolosker AMB, Paiva ER, de Abreu MT, Maciel RMB (1998) Prospective and Controlled Study of Ophthalmopathy After Radioiodine Therapy for Graves' Hyperthyroidism. Thyroid 8: 49-52
48. Moka D, Dietlein M, Schicha H (2002) Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med 29: 486-491
49. Moka D, Schicha H, Körber C, Schneider P, Reiners C (2000) Reduzieren Thyreostatika die Erfolgsrate in der Radioiodtherapie? Nuklearmedizin 2: N25
50. Moll GW, Pathel BR (1997) Pediatric Graves' Disease: Therapeutic Options and Experience With Radioiodine at the University of Mississippi Medical Center. South Med J 90: 1017-1022
51. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S (2002) Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. Eur J Endocrinol 147: 583-589
52. Noury AMS, Stanford MR, Graham EM (2001) Radioiodine and Graves' ophthalmopathy reconsidered. Nucl Med Communic 22: 1167-1169
53. Pant GS, Kumar R, Gupta AK, Sharma S K, Pandey AK (2003) Estimation of thyroid mass in Graves' disease by a scintigraphic method. Nucl Med Communic 24: 743-748
54. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA (2001) Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358: 861-865
55. 131I in hyperthyroidism. Q J Nucl Med 44: 333-339
56. Pavía C, Villanueva J, Valls C, Mañé S, Cedó J (2002) Radioiodine Therapy for Graves Disease in Adolescents: Analysis of 11 Patients. Endocrinologist 12: 17-19
57. Perros P (2000) Anti-thyroid drug treatment before radioiodine in patients with Graves' disease: soother or menace? Clin Endocrinol 53: 1-2
58. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H (1997) Treatment of Graves' Hyperthyroidism with Radioiodine: Results of a Prospective Randomized Study. Thyroid 7: 247-251
59. Pfeilschifter J, Elser H, Haufe S, Ziegler R, Georgi P (1997) Einfluß prätherapeutischer Variablen auf die Wirkung einer standardisierten 131J-Therapie mit 150 Gray beim Morbus Basedow. Nuklearmedizin 36: 81-86
60. Reinartz P, Sabri O, Zimny M, Nowak B, Cremerius U, Setani K, Büll U (2002) Thyroid Volume Measurement in Patients Prior to Radioiodine Therapy: Comparison Between Three-Dimensional Magnetic Resonance Imaging and Ultrasonography. Thyroid 12: 713-717
61. Reinartz P, Zimny M, Schaefer W, Mueller B, Buell U, Sabri O (2003) Radioiodine therapy in patients with hyperthyroid disorder: standard versus dosimetric activity application. Nucl Med Communic 24: 1247-1253
62. Reiners C (1994) Prophylaxe strahleninduzierter Schilddrü senkarzinome bei Kindern nach der Reaktorkatastrophe von Tschernobyl. Nuklearmedizin 33: 229-234
63. Reiners C (1999) Radioiodtherapie des Morbus Basedow - Aspekte zur Qualitätssicherung und zum Strahlenschutz. Z ärztl Fortbild Qualsich 93 Suppl I: 61-66
64. Reiners C, LaBmann M (2002) Die neue Strahlenschutzverordnung aus der Sicht des in der Forschung tätigen Nuklearmediziners. Nuklearmediziner 25: 18-22
65. Reinhardt MJ, Brink I, Joe AY, von Mallek D, Ezziddin S, Palmedo H, Krause TM (2002) Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculation: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med 29: 1118-1124
66. Rivkees SA, Sklar C, Freemark M (1998) The Management of Graves' Disease in Children, with Special Emphasis on Radioiodine Treatment. J Clin Endocrinol Metab 83: 3767-3776
67. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD Jr (1998) Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280: 375-376
68. Sabri O, Schulz G, Zimny M, Schreckenberger M, Zimny D, Wagenknecht G, Kaiser HJ, Dohnen BM, Bares R, Büll U (1998) Bestimmung von Einflußgrößen für den Therapieerfolg der Radioiodtherapie bei Patienten mit Morbus Basedow. Nuklearmedizin 37: 83-89
69. Sabri O, Zimny M, Buell U (2002) Influence of antithyroid drugs on the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre. Eur J Nucl Med 29: 160-161
70. Sabri O, Zimny M, Schreckenberger M, Reinartz P, Nowak B, Ostwald E, Schäfer W, Block S, Setani K, Büll U (2001) Charakterisierung von Therapieversagern bei der Radioiodtherapie des Morbus Basedow ohne simultane Thyreostase. Nuklearmedizin 40: 1-6
71. Sabri O, Zimny M, Schreckenberger M, Reinartz P, Ostwald E, Buell U (1999) Radioiodine Therapy in Graves' Disease Patients with Large Diffuse Goiters Treated with or without Carbimazole at the Time of Radioiodine Therapy. Thyroid 9: 1181-1188
72. Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, Buell U (1999) Success Rate of Radioiodine Therapy in Graves' Disease: The Influence of Thyrostatic Medication. J Clin Endocrinol Metab 84: 1229-1233
73. Scheidhauer K, Odatzidu L, Kiencke P, Schicha H (2002) Körpergewichtsentwicklung nach Radioiodtherapie einer Hyperthyreose. Nuklearmedizin 1: 47-51
74. Schicha H (1997) Stellungnahme zum Editorial von D. Emrich: Muß die hohe Hypothyreoserate nach Radioiodtherapie einer immunogenen Hyperthyreose in Kauf genommen werden? Nuklearmediziner 36: 6
75. Schicha H, Dietlein M (2002) Morbus Basedow und Autonomie - Radioiodtherapie. Nuklearmedizin 41: 63-70
76. Schlögl S, Werner E, Lassmann M, Terekhova J, Muffert S, Seybold S, Reiners C (2001) Techniques in Thyroidology - The Use of Three-Dimensional Ultrasound for Thyroid Volumetry. Thyroid 11: 569-574
77. Schneider P, Körber C, Körber-Hafner N, Hänscheid H, Reiners C (2002) Verbessert die individuelle Bestimmung der effektiven Halbwertzeit die Ergebnisse der Radioiodtherapie des Morbus Basedow? Nuklearmedizin 6: 240-244
78. Strahlenschutz in der Medizin. Richtlinie nach der Verordnung über den Schutz vor Schäden durch ionisierende Strahlung (Strahlenschutzverordnung-StrISchV) vom 22.04. 2002. Rundschreiben des Bundesministeriums für Umwelt, Naturschutz und Reaktorsicherheit vom 24.06.2002 - RS II4-II432/1
79. Surks M, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin FH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ (2004) Subclinical Thyroid Disease - Scientific Review and Guidelines for Diagnosis and Management. JAMA 291: 228-238
80. Tepmongkol S (2002) Enhancement of radioiodine uptake in hyperthyroidism with hydrochlorothiazide: a prospective randomised control study. Eur J Nucl Med 29: 1307-1310
81. Tigas S, Idiculla J, Beckett G, Toft A (2000) Is Excessive Weight Gain After Ablative Treatment of Hyperthyroidism due to Inadequate Thyroid Hormone Therapy? Thyroid 10: 1107-1111
82. Traino AC, Di Martino F, Lazzeri M, Stabin MG (2000) Influence of thyroid volume reduction on calculated dose in radioiodine therapy of Graves' hyperthyroidism. Phys Med Biol 45: 121-129
83. Turner JG, Brownlie BEW, Rogers TGH (1976) Lithium as an adjunct to radioiodine therapy for thyrotoxicosis. Lancet 1: 614-615
84. Urbannek V, Schmidt M, Moka D, Hillger HW, Voth E, Wellner U, Schicha H (2000) Influence of iodine application during radioiodine therapy in case of impending therapy failure. Nuklearmedizin 39: 108-112
85. Urbannek V, Voth E, Moka D, Schicha H (2001) Radioiodtherapie des Morbus Basedow - dosimetrischer Vergleich verschiedener Therapieregime bezüglich der Thyreostatikagabe. Nuklearmedizin 4: 111-115
86. van Isselt JW, de Klerk JMH, Koppeschaar HPF, Rijk PP (2000) Iodine-131 uptake and turnover rate vary over short in Graves' disease. Nucl Med Communic 21: 609-616
87. van Isselt JW, de Klerk JMH, van Rijk PP, van Gils APG, Polman LJ, Kamphuis C, Meijer R, Beekman F J (2003) Comparison of methods for thyroid volume estimation in patients with Graves' disease. Eur J Nucl Med Mol Imaging 30: 525-531
88. Wallaschofski H, Miehle K, Mayer A, Tuschy U, Hentschel B, Paschke R (2002) Prediction of Remission or Relapse for Graves' Hyperthyroidism by the Combined Determination of Stimulating, Blocking and Binding TSH-Receptor Antibodies after the Withdrawal of Antithyroid Drug Treatment. Horm Metab Res 34: 383-338
89. Walsh JP, Dayan CM, Potts MJ (1999) Radioiodine and thyroid eye disease. BMJ 319: 68-69
90. Ward L, Huot C, Lambert R, Deal C, Collu R, van Vliet G (1999) Outcome of pediatric Graves' disease after treatment with antithyroid medication and radioiodine. Clin Invest Med 22: 132-139
91. Wartofsky L (1997) Radioiodine Therapy for Graves' Disease: Case Selection and Restrictions Recommended to Patients in North America. Thyroid 7: 213-216
92. Weigand A, Hinzpeter B, Schicha H (1998) Deterioration of endocrine ophthalmology after radioiodine therapy in Graves' disease. Nuklearmedizin 37: 234-238
93. Wiersinga WM (1998) Preventing Graves' Ophthalmopathy. N Engl J Med 338: 121-122
94. Wiersinga WM, Bartalena L (2002) Epidemiology and Prevention of Graves' Ophthalmopathy. Thyroid 12: 855-860
95. Zöphel K, Wunderlich G, Kopprasch C, Koch R, Franke W-G, Kotzerke J (2003) Prädiktiver Wert der Thyreotropinrezeptor-Antikörper bei Bestimmung im TRAK-human-Assay der zweiten Generation nach Radioiodtherapie des Morbus Basedow. Nuklearmedizin 2: 63-70